ReviewVirologica Sinica2013
Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.
Review in Virologica Sinica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Identification of potential therapeutic drugs targeting core genes for systemic lupus erythematosus (SLE) and coexisting COVID-19: Insights from bioinformatic analyses.Immunity, inflammation and disease · 2023Article
- A neutralizing bispecific single-chain antibody against SARS-CoV-2 Omicron variant produced based on CR3022.Frontiers in cellular and infection microbiology · 2023Article
- Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics.Nature communications · 2021Article
- Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2.International journal of biological sciences · 2020Review
- G196 epitope tag system: a novel monoclonal antibody, G196, recognizes the small, soluble peptide DLVPR with high affinity.Scientific reports · 2017Article
- Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics.Frontiers in immunology · 2017Review
- Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.Nature communications · 2016Article
- Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies.Journal of virology · 2014Article
- A treatment for and vaccine against the deadly Hendra and Nipah viruses.Antiviral research · 2013Review
- N-terminal truncation of an isolated human IgG1 CH2 domain significantly increases its stability and aggregation resistance.Molecular pharmaceutics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) - for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1). Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.